Literature DB >> 15156232

Preventing Delirium at the End of Life: Lessons From Recent Research.

Donna B. Greenberg1.   

Abstract

Preservation of the ability to think clearly, in comfort, is a goal of end-of-life care. Recent research on delirium at the end of life suggests clinical strategies for prevention of cognitive impairment. Clinicians should consider early warnings of mild delirium such as impairment in attention and short-term memory by following the patient's ability to remember 3 words or to attend to digit span before the patient is disoriented. If cognitive impairment is noted, clinicians should pay attention to reversible causes. This article reviews clinical concerns about opiates, benzodiazepines, steroids, hepatic encephalopathy, timely use of neuroleptic medications, and caretaking strategies at home.

Entities:  

Year:  2003        PMID: 15156232      PMCID: PMC353038          DOI: 10.4088/pcc.v05n0201

Source DB:  PubMed          Journal:  Prim Care Companion J Clin Psychiatry        ISSN: 1523-5998


  36 in total

1.  Quetiapine associated with acute mental status changes.

Authors:  F H Sim; D G Brunet; G N Conacher
Journal:  Can J Psychiatry       Date:  2000-04       Impact factor: 4.356

2.  The delirium experience: delirium recall and delirium-related distress in hospitalized patients with cancer, their spouses/caregivers, and their nurses.

Authors:  William Breitbart; Christopher Gibson; Annie Tremblay
Journal:  Psychosomatics       Date:  2002 May-Jun       Impact factor: 2.386

3.  A prospective multicenter assessment of the Edmonton staging system for cancer pain.

Authors:  E Bruera; T Schoeller; R Wenk; T MacEachern; S Marcelino; J Hanson; M Suarez-Almazor
Journal:  J Pain Symptom Manage       Date:  1995-07       Impact factor: 3.612

4.  A symptom rating scale for delirium.

Authors:  P T Trzepacz; R W Baker; J Greenhouse
Journal:  Psychiatry Res       Date:  1988-01       Impact factor: 3.222

5.  A multicomponent intervention to prevent delirium in hospitalized older patients.

Authors:  S K Inouye; S T Bogardus; P A Charpentier; L Leo-Summers; D Acampora; T R Holford; L M Cooney
Journal:  N Engl J Med       Date:  1999-03-04       Impact factor: 91.245

6.  The impact of delirium on the circadian distribution of breakthrough analgesia in advanced cancer patients.

Authors:  B Gagnon; P G Lawlor; I L Mancini; J L Pereira; J Hanson; E D Bruera
Journal:  J Pain Symptom Manage       Date:  2001-10       Impact factor: 3.612

Review 7.  The panorama of opioid-related cognitive dysfunction in patients with cancer: a critical literature appraisal.

Authors:  Peter G Lawlor
Journal:  Cancer       Date:  2002-03-15       Impact factor: 6.860

8.  The cognitive and psychomotor effects of opioid analgesics. II. A randomized controlled trial of single doses of morphine, lorazepam and placebo in healthy subjects.

Authors:  G W Hanks; W M O'Neill; P Simpson; K Wesnes
Journal:  Eur J Clin Pharmacol       Date:  1995       Impact factor: 2.953

9.  Psychiatric morbidity in terminally ill cancer patients. A prospective study.

Authors:  H Minagawa; Y Uchitomi; S Yamawaki; K Ishitani
Journal:  Cancer       Date:  1996-09-01       Impact factor: 6.860

10.  Delirium in terminally ill cancer patients.

Authors:  M J Massie; J Holland; E Glass
Journal:  Am J Psychiatry       Date:  1983-08       Impact factor: 18.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.